Skip to main
OTLK
OTLK logo

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 0%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics Inc. has received marketing authorization in the European Union and United Kingdom for its monoclonal antibody ONS-5010/LYTENAVA, indicating the potential for significant revenue generation in the ophthalmic market, particularly for the treatment of wet age-related macular degeneration. The company's product pipeline is robust, with ONS-5010 positioned to address unmet medical needs and emerging as a new ophthalmic anti-VEGF therapy, aligning well with market demand. Additionally, the confidence in the FDA's evaluation of ONS-5010 suggests that the treatment holds promise in addressing critical patient needs, fostering an optimistic outlook for the company's future growth.

Bears say

Outlook Therapeutics Inc. faces significant risks that contribute to a negative outlook on its stock, primarily due to its reliance on ONS-5010 as the sole active development program, which could jeopardize its future if clinical trials fail or if regulatory approval is not attained. Furthermore, the company has experienced setbacks, including missing the primary endpoint of the NORSE 8 study at 8 weeks, raising concerns about the drug's efficacy and its competitive standing in the market as new treatments and biosimilars emerge. Additionally, Outlook Therapeutics may require further financing to achieve profitability, complicating its financial stability and long-term viability.

OTLK has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 0% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 5 analysts, OTLK has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.